Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during transfection (RET) gene fusion. The patient initially received cytotoxic chemotherapy with a significant radiographic response. After 4 cycles of chemotherapy, the patient was transitioned to a clinical trial using selpercatinib, a RET inhibitor, as maintenance therapy. Unfortunately, our patient developed progression of disease at the first treatment monitoring scan. Our patient suffered primary resistance t...
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Blake J McKinley Tucker W Coston Jason S Starr Source Type: research
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody
CONCLUSIONS: For patients with initially unresectable HCC and PVTT who were successfully converted by the triple combination therapy, salvage liver resection may not be necessary, especially for the patients with CR or types III-IV PVTT.PMID:38478404 | DOI:10.1093/oncolo/oyae032 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Lei Wang Jin-Kai Feng Chong-De Lu Jia-Yi Wu Bin Zhou Kang Wang Xu-Biao Wei Chao Liang Hong-Kun Zhou Jie Shi Wei-Xing Guo Wan Yee Lau Mao-Lin Yan Shu-Qun Cheng Source Type: research
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports.PMID:38478923 | DOI:10.1093/oncolo/oyae037 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Andrew C Johns Matthew T Campbell Mamie Gao Andrew W Hahn Zita Lim Emily Wang Jianjun Gao Amishi Y Shah Pavlos Msaouel Nizar M Tannir Source Type: research
Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during transfection (RET) gene fusion. The patient initially received cytotoxic chemotherapy with a significant radiographic response. After 4 cycles of chemotherapy, the patient was transitioned to a clinical trial using selpercatinib, a RET inhibitor, as maintenance therapy. Unfortunately, our patient developed progression of disease at the first treatment monitoring scan. Our patient suffered primary resistance t...
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Blake J McKinley Tucker W Coston Jason S Starr Source Type: research
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody
CONCLUSIONS: For patients with initially unresectable HCC and PVTT who were successfully converted by the triple combination therapy, salvage liver resection may not be necessary, especially for the patients with CR or types III-IV PVTT.PMID:38478404 | DOI:10.1093/oncolo/oyae032 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Lei Wang Jin-Kai Feng Chong-De Lu Jia-Yi Wu Bin Zhou Kang Wang Xu-Biao Wei Chao Liang Hong-Kun Zhou Jie Shi Wei-Xing Guo Wan Yee Lau Mao-Lin Yan Shu-Qun Cheng Source Type: research
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports.PMID:38478923 | DOI:10.1093/oncolo/oyae037 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Andrew C Johns Matthew T Campbell Mamie Gao Andrew W Hahn Zita Lim Emily Wang Jianjun Gao Amishi Y Shah Pavlos Msaouel Nizar M Tannir Source Type: research
Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma
CONCLUSIONS: Our study highlights the value of NGS in detecting BRAF, NRAS mutations and RAF fusions, expanding possibilities for targeted therapies in malignant melanoma. Belvarafenib showed clinical benefit in patients harboring these alterations. Ongoing trials will provide further insights into the safety and efficacy of belvarafenib.PMID:38470950 | DOI:10.1093/oncolo/oyae018 (Source: The Oncologist)
Source: The Oncologist - March 12, 2024 Category: Cancer & Oncology Authors: Kyoo Hyun Kim Sungmin Cho Yeyeong Jeong Eun Sil Baek Chung Lee Hyang-Joo Ryu Young Su Noh Yoon-Hee Hong Kee Yang Chung Mi Ryung Roh Byung Ho Oh Chang Gon Kim Minkyu Jung Sang Joon Shin Source Type: research
Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma
CONCLUSIONS: Our study highlights the value of NGS in detecting BRAF, NRAS mutations and RAF fusions, expanding possibilities for targeted therapies in malignant melanoma. Belvarafenib showed clinical benefit in patients harboring these alterations. Ongoing trials will provide further insights into the safety and efficacy of belvarafenib.PMID:38470950 | DOI:10.1093/oncolo/oyae018 (Source: The Oncologist)
Source: The Oncologist - March 12, 2024 Category: Cancer & Oncology Authors: Kyoo Hyun Kim Sungmin Cho Yeyeong Jeong Eun Sil Baek Chung Lee Hyang-Joo Ryu Young Su Noh Yoon-Hee Hong Kee Yang Chung Mi Ryung Roh Byung Ho Oh Chang Gon Kim Minkyu Jung Sang Joon Shin Source Type: research
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
CONCLUSION: Rucaparib demonstrated acceptable toxicity and efficacy signal as an ADT-sparing approach in patients with biochemically recurrent nonmetastatic prostate cancer. It is currently challenging to understand the optimal value of systemic therapy in this disease setting due to the rapidly changing standard of care. Additionally, there are relatively few patients with BRCAness who present with nonmetastatic hormone-sensitive prostate cancer (ClinicalTrials.gov Identifier: NCT03533946).PMID:38452035 | DOI:10.1093/oncolo/oyae030 (Source: The Oncologist)
Source: The Oncologist - March 7, 2024 Category: Cancer & Oncology Authors: Kamal Kant Sahu Haoran Li Vinay Mathew Thomas Mallory Benson Ken Boucher Sumati Gupta Manish Kohli Umang Swami Neeraj Agarwal Benjamin L Maughan Source Type: research
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
CONCLUSION: Rucaparib demonstrated acceptable toxicity and efficacy signal as an ADT-sparing approach in patients with biochemically recurrent nonmetastatic prostate cancer. It is currently challenging to understand the optimal value of systemic therapy in this disease setting due to the rapidly changing standard of care. Additionally, there are relatively few patients with BRCAness who present with nonmetastatic hormone-sensitive prostate cancer (ClinicalTrials.gov Identifier: NCT03533946).PMID:38452035 | DOI:10.1093/oncolo/oyae030 (Source: The Oncologist)
Source: The Oncologist - March 7, 2024 Category: Cancer & Oncology Authors: Kamal Kant Sahu Haoran Li Vinay Mathew Thomas Mallory Benson Ken Boucher Sumati Gupta Manish Kohli Umang Swami Neeraj Agarwal Benjamin L Maughan Source Type: research
Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.PMID:38438322 | DOI:10.1093/oncolo/oyae026 (Source: The Oncologist)
Source: The Oncologist - March 4, 2024 Category: Cancer & Oncology Authors: Santiago Cabezas-Camarero Vanesa Garc ía-Barberán Rebeca P érez-Alfayate Mar ía Elena Gómez Del Pulgar Maria Nieves Cabrera-Martin Isabel Casado-Fari ñas Pedro P érez-Segura Source Type: research
Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.PMID:38438322 | DOI:10.1093/oncolo/oyae026 (Source: The Oncologist)
Source: The Oncologist - March 4, 2024 Category: Cancer & Oncology Authors: Santiago Cabezas-Camarero Vanesa Garc ía-Barberán Rebeca P érez-Alfayate Mar ía Elena Gómez Del Pulgar Maria Nieves Cabrera-Martin Isabel Casado-Fari ñas Pedro P érez-Segura Source Type: research
